1.4. Analysis.
Comparison 1: Induction studies – vedolizumab versus placebo, Outcome 4: Development of ≥ 1 serious adverse event during induction therapy
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.